Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder : a case report

Simple item page
dc.contributor.authorRenemane, Ļubova
dc.contributor.authorRancāns, Elmārs
dc.contributor.institutionDepartment of Psychiatry and Narcology
dc.date.accessioned2024-09-05T08:15:01Z
dc.date.available2024-09-05T08:15:01Z
dc.date.issued2024-08-01
dc.descriptionPublisher Copyright: Copyright © 2024 Renemane and Rancans.
dc.description.abstractThis case report describes a patient with major depressive disorder (MDD) who developed acute hepatocellular liver injury after being treated with sertraline, a selective serotonin reuptake inhibitor (SSRI). The diagnosis of MDD was made two years prior, and the patient had previously responded partially to escitalopram and cognitive-behavioral therapy (CBT). Upon switching to sertraline 50 mg daily, the patient presented with severe symptoms indicative of acute liver injury, including elevated liver enzymes, jaundice, and gastrointestinal distress. Following the discontinuation of sertraline, the patient’s liver function tests gradually normalized over a 90-day period, confirming the diagnosis of sertraline-induced hepatotoxicity. This case underscores the importance of continuous monitoring for potential liver injury in patients treated with sertraline. The findings contribute to the existing body of evidence on the hepatotoxic risks associated with SSRIs and highlight the need for personalized treatment strategies to mitigate adverse effects and enhance patient safety. Further research is needed to explore the long-term safety and efficacy of sertraline, particularly in vulnerable populations.en
dc.description.statusPeer reviewed
dc.format.extent1110045
dc.identifier.citationRenemane, Ļ & Rancāns, E 2024, 'Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder : a case report', Frontiers in Psychiatry, vol. 15, 1456455. https://doi.org/10.3389/fpsyt.2024.1456455
dc.identifier.doi10.3389/fpsyt.2024.1456455
dc.identifier.issn1664-0640
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/16654
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85201397153&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofFrontiers in Psychiatry
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectacute liver injury
dc.subjectdrug-induced liver injury (DILI)
dc.subjecthepatocellular liver injury
dc.subjecthepatotoxicity
dc.subjectselective serotonin reuptake inhibitor (SSRI)
dc.subjectsertraline
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectPsychiatry and Mental health
dc.subjectSDG 3 - Good Health and Well-being
dc.titleSertraline induced acute hepatocellular liver injury in patient with major depressive disorder : a case reporten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Sertraline_induced_acute_hepatocellular.pdf
Size:
1.06 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure